Idraparinux sodium is an anticoagulant medication in development by Sanofi-Aventis.
It has a similar chemical structure and the same method of action as fondaparinux, but with an elimination half-life about five to six times longer (an increase from fondaparinux's 17 hours to approximately 80 hours), which means that the drug should only need to be injected once a week. Supriya Dey et al recently reported shortest chemical synthesis of Idraparinux for the large-scale production.
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).